The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.
 
Thatcher Ross Heumann
No Relationships to Disclose
 
Mark Yarchoan
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Judy Murray
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
John Joseph Wright
No Relationships to Disclose
 
Elad Sharon
No Relationships to Disclose
 
Gregory B. Lesinski
Research Funding - Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Vaccinex (Inst)
 
Nilofer Saba Azad
Consulting or Advisory Role - AstraZeneca; Helsinn Therapeutics/QED Therapeutics; Incyte; Merck; Mirati Therapeutics; QED Therapeutics
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono; Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Syndax (Inst)